Cenegermin
Recombinant Human Nerve Growth Factor — SENSORY ORGANS
Also known as: oxervate
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Cenegermin is a drug in the Recombinant Human Nerve Growth Factor class catalogued in DrugCentral. It was first approved by the EMA in 2017. DrugCentral lists 2 molecular targets, including NTRK1 and NGFR. Recorded indications include Neurotrophic keratitis.
- Drug class: Recombinant Human Nerve Growth Factor.
- Molecular targets: NTRK1 and NGFR (2 listed in DrugCentral).
- Indications: Neurotrophic keratitis.
- ATC code: S01XA24 (Other ophthalmologicals).
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Neurotrophic keratitis
Mechanism & targets
| Established pharmacologic class | Recombinant Human Nerve Growth Factor |
|---|
Molecular targets (2)
| Target | Gene | Action | Activity |
|---|---|---|---|
| High affinity nerve growth factor receptor | NTRK1 | agonist | — |
| Tumor necrosis factor receptor superfamily member 16 | NGFR | agonist | — |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2017-07-06 | EMA | — | Dompe farmaceutici s.p.a. | Yes |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
S01XA24 | SENSORY ORGANS › OPHTHALMOLOGICALS › OTHER OPHTHALMOLOGICALS › Other ophthalmologicals |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Eye pain | 2491.6 |
| Eye irritation | 694.9 |
| Ocular hyperaemia | 528.1 |
| Photophobia | 369.8 |
| Ocular discomfort | 357.0 |
| Eyelid pain | 329.0 |
| Periorbital pain | 253.1 |
| Eye swelling | 232.1 |
| Corneal deposits | 229.4 |
| Vision blurred | 225.1 |
| Therapy interrupted | 207.7 |
| Product dose omission issue | 198.9 |
Chemical structure
| Molecular formula | — |
|---|---|
| Molecular weight | — |
| CAS number | — |
| InChIKey | — |
| PubChem CID | — |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Cenegermin used for?
DrugCentral lists the following indications for Cenegermin: Neurotrophic keratitis.
How does Cenegermin work?
Its molecular targets in DrugCentral include NTRK1 (agonist) and NGFR (agonist).
When was Cenegermin first approved?
Cenegermin was first approved by the EMA in 2017.
What drug class does Cenegermin belong to?
Cenegermin is in the Recombinant Human Nerve Growth Factor class.
Browse: all drugs starting with C · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5235 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL4297852 — compound record and bioactivity
- DrugBank DB13926 — drug record
- FDA UNII B6E7K36KT8 — substance identity
- UniProt P04629 (NTRK1) — target protein
- UniProt P08138 (NGFR) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.